Checking procalcitonin suitability for prognosis and antimicrobial therapy monitoring in burn patients by Cabral, Luís et al.
RESEARCH ARTICLE Open Access
Checking procalcitonin suitability for
prognosis and antimicrobial therapy
monitoring in burn patients
Luís Cabral1,2* , Vera Afreixo3, Rita Meireles1, Miguel Vaz1, Catarina Chaves4, Marisa Caetano5, Luís Almeida6
and José Artur Paiva7,8
Abstract
Background: Due to greater infection susceptibility, sepsis is the main cause of death in burn patients. Quick
diagnosis and patient stratification, early and appropriated antimicrobial therapy, and focus control are crucial for
patients’ survival. On the other hand, superfluous extension of therapy is associated with adverse events and arousal
of microbial resistance. The use of biomarkers, necessarily coupled with close clinical examination, may predict
outcomes, stratifying patients who need more intensive care, and monitor the efficacy of antimicrobial therapy,
allowing faster de-escalation or stop, reducing the development of resistance and possibly the financial burden,
without increasing mortality. The aim of this work is to check the suitability of procalcitonin (PCT) to fulfill these
goals in a large sample of septic burn patients.
Methods: One hundred and one patients, with 15% or more of total body surface area (TBSA) burned, admitted
from January 2011 to December 2014 at Coimbra Burns Unit (CBU), in Portugal were included in the sample. All
patients had a diagnosis of sepsis, according to the American Burn Association (ABA) criteria. The sample was
factored by survival (68 survivors and 33 non-survivors). The maximum value of PCT in each day was used for
statistical analysis. Data were summarized by location measures (mean, median, minimum, maximum, quartiles) and
dispersion measures (standard error and range measures). Statistical analysis was performed with SPSS© 23.0 IBM©
for Windows©.
Results: There were statistically significant differences between PCT levels of patients from the survivor and non-
survivor groups during the first and the last weeks of hospitalization as well as during the first week after sepsis
suspicion, being slightly higher during this period. During the first 7 days of antimicrobial therapy, PCT was always
higher in the non-survivor, still without reaching statistical significance, but when the analysis was extended till the
15th day, PCT increased significantly, rapidly, and steadily, denouncing therapy failure.
Conclusion: Despite being not an ideal biomarker, PCT proved to have good prognostic power in septic burn
patients, paralleling the evolution of the infectious process and reflecting the efficacy of antimicrobial therapy, and
the inclusion of its serial dosing may be advised to reinforce antimicrobial stewardship programs at burn units;
meanwhile, more accurate approaches are not available.
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Background
Sepsis is still nowadays the main cause of death in burn
patients due to the impact of extensive burns in all
organ systems, affecting homeostatic mechanisms, and
to the greater susceptibility of this population to infec-
tion [1, 2], related to the loss of the cutaneous barrier,
immunosuppression, use of invasive devices, nosocomial
flora, etc. Survival is directly dependent on the institu-
tion of prompt and adequate antimicrobial therapy [3].
However, the gold standard for sepsis diagnosis still re-
lies on the identification of microorganisms in blood
cultures, which unfortunately are positive only in 20–
30% of all confirmed bloodstream infections, and their
results may take 48 to 72 h to reach the prescriber [4].
While more rapid methods of microbiological identifica-
tion, such as polymerase-chain reaction (PCR) [5],
matrix-assisted laser desorption ionization–time of
flight mass spectrometry (MALDI-TOF MS), gene ex-
pression profiling, aptamer panels, etc. [6], are not either
widely available or fully developed, the use of early em-
pirical often broad-spectrum antibiotic therapy is war-
ranted. This empirical strategy increases the likelihood
of cure of infection and survival but negatively impacts
in terms of microbiome, leading to the selection and
emergence of antimicrobial resistance. In this context,
biochemical biomarkers, namely procalcitonin (PCT)
alone [7, 8] or integrating a composite panel [9–12], and
always coupled with thorough clinical examination, may
be an important aid for the early suspicion of sepsis and
rapid institution of therapy, which is strongly associated
with improved outcomes [13, 14].
PCT is a 116-amino acid precursor of calcitonin,
which synthesis and secretion, encoded by first calci-
tonin gene (CALC-I gene), and normally restricted to
thyroid C cells and some neuroendrocrine cells of the
lungs and gut, is upregulated by the presence in the
blood of microbial toxins, necrotic body cells, and some
proinflammatory cytokines (IL-1, IL-6, TNF-α, etc.), in a
synergistic way, starting to be produced in great
amounts by many other nonendocrine types of cells, in-
cluding monocytes and adipocytes [15], reaching meas-
urable levels in 2–4 h after onset of the infectious
process, peaking at 24–30 h, and rapidly subsiding with
recovery. PCT increment is less pronounced with fungal
infection and is absent in viral disease, allegedly due to
inhibition of its secretion by some cytokines released as
a response to viral infection, like interferon-γ [16].
Besides its utility to help clinicians in the diagnosis of
sepsis [17] including patients admitted to burn units [18],
the magnitude and duration of PCT elevation seems to
correlate with injury severity and outcome, and there are
several published works analyzing its potential for the
prognosis and for the monitoring of antimicrobial therapy,
helping decisions on early antibiotic de-escalation or res-
cue therapy [19–21]. Most of these are focused in lower
respiratory tract infections and/or intensive care patients,
while papers on septic burn patients are scarce [22].
The purpose of this work is to evaluate the feasibility
of PCT use to predict the outcome and to monitor the
efficacy of antimicrobial therapy in a sample of severe
adult burn patients.
Methods
The sample under analysis was composed by 101 burn
patients, with 15% or more of total body surface area
(TBSA) burned, admitted from January 2011 to
Table 1 Patients’ characteristics
Characteristics Survivors Non-survivors p value
Number of patients 68 33
Age (years) 53.0 ± 2.4
(18–85)
70.5 ± 3.5
(28–90)
0.000*
Male, gender (%) 38 (55.9%) 19 (57.6%) 0.872
Burn degree (2nd/2nd and 3rd/3rd) 8/50/10 1/24/8 0.219
ABSI score 8.0 ± 0.2
(4–13)
10.4 ± 0.4
(8–17)
0.000*
TBSA burned (%) 28.2 ± 1.6
(14–75)
40.7 ± 3.6
(15–90)
0.000*
Inhalation injury (%) 45 (66.2%) 15 (45.5%) 0.047*
Mechanical ventilation (%) 36 (52.9%) 4 (12.1%) 0.000*
Days of mechanical ventilation 11.3 ± 2.3
(0–70)
22.4 ± 3.8
(0–76)
0.000*
Duration of sepsis episode (days) 5.5 ± 0.6
(1–24)
10.6 ± 1.8
(1–43)
0.005*
Antimicrobial therapy (days) 20.8 ± 2.4
(0–104)
18.5 ± 3.4
(0–64)
0.374
Number of surgical interventions 4.3 ± 0.3
(0–15)
2.5 ± 0.6
(0–12)
0.000*
Length of stay (days) 43.1 ± 3.2
(8–180)
29.9 ± 5.0
(3–113)
0.001*
Values are mean ± S.E. (min-max)
*Significant difference at p value < 0.05
ABSI Abbreviated Burn Severity Index, TBSA Total body surface area,
S.E. Standard error
Table 2 Analysis of individual procalcitonin (PCT) location
measures in survivor and non-survivor patients, showing
statistically significant differences for all parameters
Survivors Non-survivors p value
PCT
minimum
0.10 ± 0.01 (0.02–0.39) 2.84 ± 1.59 (0.06–48.39) 0.000*
PCT
median
0.57 ± 0.10 (0.05–4.31) 4.73 ± 1.93 (0.27–58.99) 0.000*
PCT
mean
2.04 ± 0.48 (0.05–26.28) 7.00 ± 1.98 (0.05–58.99) 0.000*
PCT
maximum
18.40 ± 4.38 (0.07–237.60) 28.07 ± 5.98 (0.87–145.40) 0.002*
Values are mean ± S.E. (min-max)
*Significant difference at p value < 0.05
PCT procalcitonin, S.E. Standard error
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December 2014 at Coimbra Burns Unit (CBU), a depart-
ment of Coimbra Hospital and University Center
(CHUC), in Portugal. Being a retrospective observational
study of patients from a suitably anonymized dataset, in-
volving only recording data from the medical record, the
Ethics Committee from CHUC, according to the Declar-
ation of Helsinki and Council for International Organi-
zations of Medical Sciences (CIOMS) International
Ethics Guidelines, waived the need of informed consent.
All the patients had a diagnosis of sepsis. This diagnosis
was done according to the American Burn Association
(ABA) criteria [23]: a clinical suspicion of infection
coupled with the presence of three or more of the follow-
ing parameters: temperature > 39 or < 36.5 °C; tachycardia
> 110 beats per minute; tachypnea > 25 breaths per mi-
nute or minute ventilation > 12 L/min; thrombocytopenia
< 100,000/μL; hyperglycemia (untreated plasma glucose >
200 mg/dL or intravenous glucose requirement > 7 U/h
over 24 h); and enteral feeding intolerance: abdominal dis-
tension or gastric residuals more than two times feeding
rate or diarrhea > 2500 mL/24 h.
PCT was measured with time-resolved amplified cryp-
tate emission (TRACE) technology (Kryptor PCT;
Brahms AG; Hennigsdorf, Germany). The sample was
factored by survival (68 survivors and 33 non-
survivors). The maximum value of PCT in each day of
the study was used for statistical analysis and when sam-
ples were not collected in some days (till a maximum of
5 days), the missing values of the interval were calcu-
lated as the median value between the PCT determina-
tions available.
Statistical analysis
Data were summarized by location measures (mean, me-
dian, minimum, maximum, quartiles) and dispersion
measures (standard error and range measures).
Fig. 1 Box plots of individual procalcitonin (PCT) median according to survivor and non-survivor groups. *p < 0.05 means significant differences
Table 3 Evolution of procalcitonin levels during the first
week of hospitalization for survivor and non-survivor groups
First week of hospitalization
Survivors Non-survivors
Day N Median Q1–Q3 N Median Q1–Q3
1 58 0.290 0.150–1.160 27 1.6600 0.405–7.995
2 65 0.345 0.170–1.650 28 2.0550 0.270–6.840
3 66 0.360 0.170–1.640 27 1.9800 0.565–3.220
4 67 0.420 0.175–1.155 26 2.0550 0.520–4.170
5 67 0.345 0.160–0.830 26 1.7900 0.700–4.370
6 68 0.330 0.155–0.785 25 1.3100 0.560–2.850
7 68 0.360 0.160–0.985 24 1.7000 0.730–5.555
Q1-Q3 1st Quartile- 3rd Quartile
Table 4 Evolution of procalcitonin levels in the last week of
hospitalization for survivor and non-survivor groups
Last week of hospitalization
Survivors Non-survivors
Day N Median Q1–Q3 N Median Q1–Q3
1 67 0.180 0.100–0.395 22 1.050 0.700–2.370
2 68 0.160 0.095–0.435 24 1.0150 0.435–2.830
3 68 0.150 0.080–0.400 26 1.1100 0.560–2.510
4 68 0.160 0.080–0.320 26 1.2000 0.460–2.825
5 68 0.150 0.070–0.355 27 1.4700 0.650–3.570
6 68 0.140 0.070–0.360 28 2.3650 0.710–5.820
7 68 0.125 0.070–0.365 31 3.8200 1.100–10.235
Q1-Q3 1st Quartile- 3rd Quartile
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The variables under study present a non-Gaussian distri-
bution. Under a nonparametric approach, the quantitative
variables were compared with the Mann-Whitney U tests
and qualitative variables were compared with the Pearson
chi-square test. Time variations of PCT levels were tested
using Friedman’s test and Kendall’s W ranges from 0 (no
agreement) to 1 (complete agreement).
To measure the difference effect size between the two
independent groups, the probability of superiority (PS)
was used. PS ranges from 0.0 to 1.0 and PS = 0.5 state
that there are no differences between the groups [A] and
PS = 0 or PS = 1 states the maximum effect.
Statistical analysis was performed with SPSS© 23.0
IBM© for Windows©, and in a statistical hypothesis
test, a p value ≤ 0.05 means the effect was consid-
ered significant.
Results
Sample description
Population characteristics are described in Table 1.
After factorization by survival, a significant hetero-
geneity was found between the two groups (68 survi-
vors and 33 non-survivors) for the age of the
patients, the Abbreviated Burn Severity Index (ABSI)
Fig. 2 Line plots of procalcitonin (PCT) levels evolution along the first week of hospitalization (a), last week of hospitalization (b), first week after suspicion
of sepsis (c), and first week of antimicrobial therapy (d), showing significant differences between survivor and non-survivor groups in a, b, c, d
Cabral et al. Burns & Trauma  (2018) 6:10 Page 4 of 10
score (Additional file 1) [24], the TBSA burned, the
presence of inhalation injury, the need of mechanical
ventilation and its duration, the number of surgical
interventions, the duration of sepsis episode, and the
length of the stay at the burn unit. Heterogeneity
was not found for gender, burn degree, and duration
of antimicrobial therapy.
Table 2 shows the comparison of individual PCT loca-
tion measures, presenting significant differences between
survivors and non-survivors in all statistical parameters
(minimum, median, mean, maximum).
The box plots of individual median PCT levels for
each group are presented in Fig. 1, being significantly
lower for survivors.
PCT evolution along the first week of stay
Table 3 shows the evolution PCT levels in patients from
the survivor and non-survivor groups during the first
week of stay at CBU. The data presents missing values
of the PCT in some of the days of hospitalization and
this is the reason for this variation in the number of in-
dividuals by scenario. Differences between PCT levels of
patients from the survivor and non-survivor groups dur-
ing the first week of hospitalization are statistically sig-
nificant (Fig. 2a and Table 6).
PCT evolution along the last week of stay
The evolution of PCT levels for survivor and non-
survivor groups in their last week of stay at CBU is pre-
sented in Table 4. A statistically significant difference
was also demonstrated for this period of time (Fig. 2b
and Table 6).
PCT evolution in the first week after suspicion of sepsis
A statistical analysis of PCT evolution in the first week
after suspicion of sepsis, as defined by ABA criteria, was
also carried out. Data are presented in Table 5. A signifi-
cant difference between survivor and non-survivor
groups was detected (Fig. 2c and Table 6).
In order to compare the relative prognostic value of
PCT levels in each of the abovementioned periods (first
week of hospitalization, last week of hospitalization, and
first week after sepsis suspicion), statistical tests were
done, namely Friedman test p value and Mann-
Whitney U test p values with Sidak correction (Table 6).
Furthermore, the PS effect [25] was determined. The
results are transcribed in Table 7.
PCT evolution with antimicrobial therapy
No statistically significant difference was found between
the groups, but a within-group significant variation was
detected, with a progressive decline along the first 7 days,
supposedly due to antimicrobial action (Fig. 2d and
Table 8). When the analysis was extended to the 15th
day, it was found that PCT levels increased rapidly and
steadily until the day of death in non-survivors, what did
not happen in the survivor group, as seen in Fig. 3.
Discussion
Even acknowledging all advances in critical care, extensive
burns are still associated with high morbidity and mortality
mainly due to septic episodes [26, 27]. In the last years, di-
verse studies were published showing the utility of dosing
PCT levels as an aid to the diagnosis of systemic infection
in burn patients [28–34], particularly when a dynamic ap-
proach is used [35]. Notwithstanding the core decision
should rely on the clinical features and never on a bio-
marker alone [36], PCT dosing may support the suspect of
Table 5 Evolution of procalcitonin levels during the first week
after suspicion of sepsis for survivor and non-survivor groups
First week after suspicion of sepsis
Survivors Non-survivors
Day N Median Q1–Q3 N Median Q1–Q3
1 58 0.385 0.160–2.260 26 1.915 0.460–6.170
2 63 0.600 0.200–2.430 27 2.100 0.560–6.735
3 65 0.610 0.200–2.120 26 2.310 0.550–5.610
4 65 0.400 0.200–1.170 24 1.850 0.485–5.965
5 64 0.395 0.210–1.160 23 1.270 0.545–3.820
6 60 0.345 0.170–1.240 21 1.300 0.720–4.910
7 52 0.330 0.160–1.470 20 0.930 0.515–2.350
Q1-Q3 1st Quartile- 3rd Quartile
Table 6 Comparison between survivors and non-survivors during three periods of stay (first week of stay, last week of stay, and first
week after suspicion of sepsis)
Period Survivors Non-Survivors Global difference
p valuea Kendall’s W N p valuea Kendall’s W N p valueb
First week of stay 0.925 0.006 58 0.504 0.042 21 0.000*
Last week of stay 0.000* 0.162 67 0.050 0.095 22 0.000*
First week after suspicion of sepsis 0.000* 0.117 46 0.217 0.077 18 0.002*
Significant difference (*p value < 0.05)
aFriedman test p value
bThe minimum p value of all simultaneous Mann-Whitney U tests with Sidak correction
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ongoing and uncontrolled systemic infection when its
values keep rising, or at least does not subside in consecu-
tive analysis, indicating that something must be done to
control a probable septic process before it can lead to irre-
versible damage. Apart its potential to improve clinicians’
diagnostic capacity, PCT has been used with success at the
emergency departments [37, 38], to predict the prognosis
of suspected septic patients and to stratify them according
to the risk of death and the necessity of admission in inten-
sive care units (ICU) [39–41]. PCT levels at admission and,
much more reliable [42], its evolution on subsequent days
may give insights on the ultimate outcome, which is crucial
to clinical management and may be of great importance to
inform patient’s relatives and for judicial concerning [43–
47]. This valuable predictive power was not found for C-
reactive protein (CRP) or white blood cells counting,
another currently employed blood biomarkers [48–53]. The
prognostic power of PCT dosing has also been stated for
burned patients by Kim et al. [54] who, in a prospective ob-
servational study with a cohort of 175 patients, showed a
significant correlation between PCT levels and mortality
rate. In this context, it is worth to note, as referred by
Piroglu et al. [55], that clinical scoring systems used to pre-
dict mortality of intensive care patients, like Acute Physi-
ology and Chronic Health Evaluation Score II (APACHE
II), Simplified Acute Physiology Score (SAPS), Sequential
Organ Failure Assessment (SOFA), and Pediatric Risk of
Mortality (PRISM), do not include parameters specific for
burn patients, and these authors showed that combination
of the former score with PCT significantly increased its
accuracy. A prospectively study of Lavrentieva et al. [31],
including 145 patients, concluded that the maximum PCT
level has prognostic value in burn patients, and Mokline
et al. [32] found a close correlation of PCT levels with
sepsis severity, showing that increasing values were
linked with worse outcomes and vice versa.
Another important use of PCT dosing is guiding anti-
microbial therapy in septic ICU patients, which is becom-
ing generally accepted [56], supported by several trials
[57–62], systematic reviews, and meta-analysis [63–67];
however, some authors still consider that more studies on
its safety and efficacy are needed yet [68, 69]. Once a clin-
ical suspicion of sepsis is done, and in particular if corrob-
orated by abnormally elevated PCT levels, empirical
antimicrobial therapy, coupled with focus control when
feasible, must be immediately started because survival is
mostly depending on it and any delay, even hourly, is dir-
ectly related with an increase in mortality [13, 70, 71]. On
the other hand, there is an overwhelming acceptation that
a lengthening of antimicrobial therapy beyond that strictly
necessary to control the infectious process favors the de-
velopment of microbial resistance, contributing to the
soaring public health risk of having each time less sensi-
tive microorganisms and lack of antimicrobials to combat
them [72]. Many published works describe PCT kinetics
as a mirror of the evolution of the infectious episode [73–
75] as well as a trustable indicator of the antimicrobial
therapy efficacy, allowing an early de-escalation and/or
stopping of drug administration when its levels progress
and consistently subside [76, 77]. When PCT levels keep
elevated or even increasing, this is a sound indication that
therapy is not working and/or that there are still infectious
foci to clean, and if the situation is not rapidly controlled,
a bad outcome is foreseeable.
Several authors have discussed in recent works this
use of PCT, and a body of evidence is growing to sup-
port this approach. Jensen et al. in a trial (PASS Study)
[78] published in 2011 advised against PCT-guided anti-
microbial escalation, linking it to increased organ-related
harm and length of stay at the ICU, without improve-
ment in the outcomes. However, the sample analyzed
came from just one developed country with antimicro-
bial restriction and a traditionally low microbial resist-
ance. On the other hand, focus was not put on the
possibility of using PCT levels to help decision on anti-
biotherapy discontinuation neither a subgroup analysis
Table 7 Probability of superiority (PS) effect in procalcitonin levels due to mortality in different periods of stay (first week of stay, last
week of stay, and first week after suspicion of sepsis)
PS effect D1 D2 D3 D4 D5 D6 D7
First week of stay 0.29 0.26 0.25 0.25 0.21 0.24 0.25
Last week of stay 0.06 0.10 0.13 0.15 0.16 0.20 0.15
First weak after suspicion of sepsis 0.32 0.30 0.31 0.28 0.28 0.24 0.29
Table 8 Evolution of procalcitonin levels in the first week of
antimicrobial therapy for survivor and non-survivor groups
First week of antimicrobial therapy
Day Survivors Non-survivors
N Median Q1–Q3 N Median Q1–Q3
1 66 0.6300 0.240–3.020 24 2.080 0.945–2.810
2 68 0.5500 0.225–2.475 24 2.680 0.870–5.155
3 66 0.4950 0.220–1.300 24 1.945 0.750–7.205
4 66 0.4400 0.220–1.140 23 2.010 0.940–4.485
5 65 0.3500 0.170–1.140 22 1.065 0.550–4.490
6 61 0.3700 0.170–1.250 21 1.070 0.380–3.270
7 59 0.3700 0.175–0.920 21 0.960 0.660–2.420
Q1-Q3 1st Quartile- 3rd Quartile
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on burn patients was done. Nevertheless, and even if
antimicrobial escalation may be somewhat controversial,
PCT has proven to be very useful to monitor antimicro-
bials efficacy, with its levels paralleling clinical evolution,
and to indicate when it is safe to stop it without preju-
dice to the patients [79]. Indeed, this methodology has
proved to safely decrease antimicrobial consumption
[80] by reducing days of antimicrobial therapy with
strong potential to lower resistance development. This
approach has already been validated for use in ICUs,
with proven reduction of antimicrobial consumption
without increase in morbidity or mortality [81]. Indeed,
de Jong et al., in the largest prospective study in ICU pa-
tients published to date (SAPS Study) [61], were even
able to show a significant reduction of mortality rate.
The ever wider diffusion of PCT test, reducing its costs,
and its efficacy in this setting, made also possible for
some authors to consider it as probably cost-effective
[82–86]. In a recent paper, Lavrentieva et al. [87] re-
ported significantly shorter durations of antibiotic treat-
ment in a PCT-guided group of burns patients
compared to controls without differences in main out-
come characteristics, including mortality rate, length of
mechanical ventilation, and length of stay.
Among the limitations of this study are naturally its
single-center, retrospective observational character as
well as lacking of subgroup analysis according to con-
comitant pathologies. The definition of a precise cut-
off of PCT levels for predicting outcomes or stopping
antimicrobial therapy was also beyond the scope of
this analysis and, as recognized in the literature, it
will always be dependent on patient characteristics
and facility features, and it is PCT kinetics that de-
served authors attention, in spite of 100 ng/mL was
often taken as an alert signal. On the positive aspects
are the sample size and the strict use of ABA burn
sepsis definitions for inclusion criteria. The strength
of results from the present study would be largely en-
hanced by a desirable prospective multicentric trial.
The use of prognostic biomarkers in order to pre-
dict outcomes as well for guiding antimicrobial ther-
apy in sepsis patients is nowadays a common
practice in intensive care wards. As anytime more
acknowledged in the literature, antimicrobial stew-
ardship programs employing current available bio-
markers or preferably, a panel of diverse ones,
always associated with repeated clinical evaluation,
may decisively improve patients’ stratification and
antimicrobial use, optimizing patients outcome, re-
ducing the spread of microbial resistance, and cut-
ting financial burden [88–93]. Meanwhile more
sophisticated and individualized system-based (inte-
grating genomics, metabolomics, and proteomics)
[94–96] data are not available to more accurately
predict outcomes and tailor treatment options for
burn victims, as well as other intensive care patients,
PCT dosing will remain one of the more useful tools
to help clinicians decisions.
Fig. 3 Line plots of procalcitonin (PCT) evolution in the first 15 days of antimicrobial therapy
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Conclusion
In spite of its limitations, the close correlation be-
tween PCT levels and patients’ outcomes statistically
demonstrated in the present work backs its use for
prognosis determination in severe burn patients.
Additionally, this study showed that the persistency
of abnormally elevated PCT along the days of anti-
microbial therapy was linked with poor outcomes in
this set of patients, opposed to what happens when
their levels fall in a consistent way, reflecting its
efficacy.
Prospective multicentric studies would surely give
more strength to the generalization of PCT use for prog-
nosis and antimicrobial stewardship in burn patients and
are much needed.
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